Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: Aflibercept Dosing by Imaging in Diabetic Retinopathy
NCT03531294Phase 2Completed
- Sponsor
- Greater Houston Retina Research Center
- Start
- May 2018
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in diabetic retinopathy (DR), sponsored by Greater Houston Retina Research Center. Started May 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03531294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531294.